Because bone-forming environments tend to be hypoxic and because the inhibition of HIF1α, a hypoxia-sensing protein, abrogates HO formation in models of FOP, HIF1α is a potent target for FOP therapies. This evidence concerns the gene HIF1A and fibrodysplasia ossificans progressiva.